Emily Campbell, MD
Allergy · Nashville, TNNPI 1699136515
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,176 of the $5,667 with a category attached, or 73.7%. Pharming Healthcare, Inc. accounts for 90.9% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $4,554, 5.8 times the $791 reported in 2023.
Across 26 payments — averaging $217.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$5K
- X4 Pharmaceuticals, Inc.$135
- Organon$80
- Blueprint Medicines Corporation$69
- Johnson & Johnson$55
- Grifols USA, LLC$53
- plus $121 from 5 others
What the payments were for
- Consulting fees$4,17674%
- Travel & lodging$57410%
- Food & beverage$91816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 13 | $5,154 |
| X4 Pharmaceuticals, Inc. | 1 | $135 |
| Organon | 1 | $80 |
| Blueprint Medicines Corporation | 1 | $69 |
| Johnson & Johnson | 2 | $55 |
| Grifols USA, LLC | 2 | $53 |
| Genentech USA, Inc. | 2 | $39 |
| Lilly USA, LLC | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $20 |
| Novartis | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 19 | $61,594 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,700 |
| Azelastine Hcl | 16 | $523 |
| Fluticasone Propionate | 22 | $257 |
| Montelukast Sodium | 15 | $188 |
| Azithromycin | 24 | $77 |
Paid to pharmacies, not to this prescriber.
Other allergy in Nashville
- David HagamanNashville$446K
- Keegan SmithNashville$978
- Michael DaoNashville$175
- Neil WallenBristol$12K
- Ryan SullivanSpring Hill$5K
- Leslie NewmanSmyrna$5K
- Chrishana OgilvieGermantown$2K
- Martha ButterfieldSmyrna$2K
- Steve ColeMemphis$1K
- Kimberly BergeronBrentwood$532
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.